Calculation Tables. Olerup SSP Kits without Taq Polymeras
|
|
|
- Moses Alexander
- 5 years ago
- Views:
Transcription
1 Calculation Tables lerup SSP Kits without Taq Polymeras
2 Table 1: Volumes of the components needed per test for different numbers of when using Master Mix without. The recommended volumes listed below include volume to compensate for pipette variations and for losses of liquid on the interior walls of the tubes. per test Master mix (μl) sample (μl) (μl) taq polymerase (μl) Table 2: Volumes of the components needed per test for different lerup SSP products when using Master Mix () including. The recommended volumes listed below include volume to compensate for pipette variations and for losses of liquid on the interior walls of the tubes. LW RESLUTIN KITS AND CMBI TRAYS name + + HLA - A HLA-A low 3E ,1 2,9 360 HLA - A HLA-A low Screening 82Y ,8 2,2 270 HLA - B HLA-B low 3F ,4 5,6 700 HLA - B HLA-B low Screening 8E ,7 4,3 540 HLA - C HLA-C low 3F ,1 2,9 360 HLA - C HLA-C low Screening 2G ,8 2,2 270 HLA - DR DR low 1E ,1 2,9 360 HLA - DR DR low Screening 4E ,8 2,2 270 HLA - DQ DQ low 9F ,6 1,4 180 Combi A-B-DR 9F ,7 8, A-B-C 8F ,7 8, A-B-DR-DQ 6F ,7 8, DQ-DR 6F ,7 4,3 540 DQA-DQB-DR Enhanced 5F ,7 8,3 1040
3 HIGH RESLUTIN KITS HIGH RESLUTIN KITS name + + name + + HLA-A HLA-A*01 1E HLA-A*02 8F ,7 8, HLA-A*03 6F ,4 5,6 700 HLA-A*23 0G ,6 3,4 420 HLA-A*24 3F ,7 8, HLA-A*25 8D ,6 1,4 180 HLA-A*26 1F ,7 4,3 540 HLA-A*34 87Y ,9 1,1 140 HLA-A*66 9E ,6 1,4 180 HLA-A*11 4E ,4 5,6 700 HLA-A*29 9F ,4 2,6 320 HLA-A*30 45Y ,1 2,9 360 HLA-A*31 4F HLA-A*32 5E ,3 2,7 340 HLA-A*33 7F ,1 2,9 360 HLA-A*74 1G ,6 1,4 180 HLA-A*80 5F ,4 0,6 70 HLA-A*36 8F ,2 0,8 100 HLA-A*68 4E ,7 4,3 540 HLA-A*69 0G ,4 0,6 80 HLA-B HLA-B*51 7E ,6 7,4 920 HLA-B*52 0G ,1 1,9 240 HLA-B*07 4F HLA-B*08 3E ,7 4,3 540 HLA-B*44 8F ,4 5,6 700 HLA-B*45 0G ,6 1,4 180 HLA-B*13 9E ,2 2,8 350 HLA-B*14 9F HLA-B*15 3F ,7 8, HLA-B*38 6F ,3 2,7 340 HLA-B*39 9F HLA-B*57 7E ,1 2,9 360 HLA-B*58 7E ,2 2,8 350 HLA-B*18 8F ,5 3,5 440 HLA-B*54 7E HLA-B*55 9E ,1 2,9 360 HLA-B HLA-B*56 0F ,8 2,2 270 HLA-B*27 5F ,7 4,3 540 HLA-B*35 2E HLA-B*40 5F ,7 8, HLA-B*37 7F ,3 2,7 340 HLA-B*41 2F ,8 2,2 270 HLA-B*42 3E ,6 1,4 180 HLA-B*46 8E ,8 2,2 270 HLA-B*47 4F ,9 1,1 130 HLA-B*48 8E ,2 1,8 230 HLA-B*49 4E ,1 1,9 240 HLA-B*50 7F ,8 2,2 270 HLA-B*53 5E ,8 2,2 270 HLA-B*59 4F HLA-B*67 7F ,2 0,8 100 HLA-B*73 80Y ,6 1,4 170 HLA-B*78 1G ,6 1,4 180 HLA-B*81 8E HLA-B*82 2E ,4 0,6 80 HLA-C HLA-C*03 6E HLA-C*04 0F ,4 5,6 700 HLA-C*05 0E ,6 3,4 420 HLA-C*06 2E HLA-C*07 7E ,7 8, HLA-C*01 2E ,1 2,9 360 HLA-C*02 2E HLA-C*08 61Y ,1 2,9 360 HLA-C*12 1F ,7 4,3 540 HLA-C*14 3F ,2 2,8 350 HLA-C*15 1D ,5 3,5 440 HLA-C*16 7E ,8 2,2 270 HLA-C*17 1E ,6 1,4 180 HLA-C*18 8F ,2 0,8 100 HLA-C direct to high resolution for frequent alleles 0F ,7 8,3 1040
4 HIGH RESLUTIN KITS SCREENING KITS FR DISEASE ASSCIATED HLA ALLELES name + + name + + HLA-DR DRB1*01 9E ,8 2,2 270 DRB1*15 2F ,1 2,9 360 DRB1*16 7F ,6 1,4 180 DRB1*03 8E ,1 2,9 360 DRB1*04 3F ,7 4,3 540 DRB1*11 7F ,7 4,3 540 DRB1*13 1F DRB1*14 3F ,7 4,3 540 DRB1*07 3E DRB1*08 2F ,8 2,2 270 DRB1*12 6F ,8 2,2 270 DRB1*09 5F ,6 1,4 170 DRB1*10 6F ,4 0,6 70 DRB3 7F ,8 4,2 520 DRB4 3D ,7 1,3 160 DRB5 5F ,2 1,8 220 DRA 52F ,7 0,3 40 HLA-DQ DQB1*05 1F ,1 2,9 360 DQB1*06 5E ,4 5,6 700 DQB1*02 98Y ,8 2,2 270 DQB1*03 6F ,4 5,6 700 DQB1*04 5E ,2 1,8 220 DQB1 direct to high resolution for frequent alleles 2F ,7 8, DQA1 3F ,1 2,9 360 HLA-DP DPB1 7F ,7 8, DPA1 2E ,6 1,4 180 HLA-B B*27 unit dose 5F ,7 0,3 40 HLA-DQ NULL ALLELE KITS HLA-B*57:01 5E ,9 2,1 260 HLA-B*51,52 7F ,6 0,4 50 DQB1*06:02, DQA1*01:02 DQA1*02,05; DQB1*02,03:02 name 1E ,2 0, F HLA-A HLA-A*24:09N 2E ,6 0,4 50 HLA-B HLA-B*51:11N 4F ,6 0,4 50 HLA-C HLA-C*04:09N 5F ,6 0,4 50 HLA-DR DRB4*01:03:01:02N 6F ,6 0,4 50 DRB5*01:08N 5F ,6 0,4 50
5 ADD-NS name + + HLA-A HLA-A*11 add-on 0G ,6 0,4 50 HLA-A*23 add-on 8F ,5 0,5 60 HLA-A*01 add-on 0E ,6 0,4 50 HLA-A*03 add-on 3F ,6 0,4 50 HLA-A*24 add-on 3F ,5 0,5 60 HLA-A*68 add-on 2E ,6 0,4 50 HLA-B HLA-B*07 add-on 4E ,2 0,8 90 HLA-B*39 add-on 4E ,6 0,4 50 HLA-B*15 add-on 8E ,6 0,4 50 HLA-C HLA-C*04 add-on 6E ,4 0,6 70 HLA-C*07 add-on 0F ,2 0,8 100 HLA-C*08 add-on 6E ,4 0,6 70 HLA-C*15 add-on 5E ,5 0,5 60 HLA-DR DRB1*14:01/14:54 0G ,6 0,4 50 DRB1*04 add-on 4F ,5 0,5 60 DRB1*12 add-on 9F ,5 0,5 60 KIR name + + KIR KIR Genotyping 9F ,5 2,5 310 KIR HLA Ligand 39Y ,2 0,8 90 Manufactured by lerup SSP AB Distributed by lerup lerup SSP AB is IS 9001:2008 and IS 13485:2003 certified. lerup SSP AB typing kits are CE-marked in accordance with the requirements of the IVD Directive 98/79/EC. lerup SSP HLA Typing Kits are FDA cleared and licensed by Health Canada. SSP CareDx, Inc. All service marks and trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved. LK Rev. 1 08/16
Calculation Tables. Olerup SSP Kits without Taq Polymeras
Calculation Tables lerup SSP Kits without Polymeras Table 1: Volumes of the components needed per test for different numbers of when using Master Mix without. The recommended volumes listed below include
ASHI Proficiency Testing Program Summary Report. Survey 2013-HT1 / HLA Typing
ASHI Proficiency Testing Program Summary Report Survey 2013-HT1 / HLA Typing Shipping Date: February 26,2013 / Results Due Date:April 5,2013 / Report Date: May 17,2013 The ASHI HT proficiency testing survey
The Human Major Histocompatibility Complex
The Human Major Histocompatibility Complex 1 Location and Organization of the HLA Complex on Chromosome 6 NEJM 343(10):702-9 2 Inheritance of the HLA Complex Haplotype Inheritance (Family Study) 3 Structure
STEP-programme S-candiaT-ransplant kidney E-xchange P-rogramme (STEP) Version 1.8
STEP-programme S-candiaT-ransplant kidney E-xchange P-rogramme (STEP) Version 1.8 June 12, 2017 General guidelines Purpose To increase the likelihood of offering a suitable kidney graft to immunized (HI)
Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director
Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director JHMI Patient Population Adults Peds NMDP data >20,000 HSCT JHMI HSCT Protocols Bone marrow
Evaluation of MIA FORA NGS HLA test and software. Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group
Evaluation of MIA FORA NGS HLA test and software Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group Disclosure Alpha and Beta Studies Sirona Genomics Reagents,
2/10/2016. Evaluation of MIA FORA NGS HLA test and software. Disclosure. NGS-HLA typing requirements for the Stanford Blood Center
Evaluation of MIA FORA NGS HLA test and software Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group Disclosure Alpha and Beta Studies Sirona Genomics Reagents,
OPTN/UNOS Policy Notice Review of HLA Tables (2016)
Review of HLA Tables (2016) Sponsoring Committee: Policy/Bylaws Affected: Histocompatibility Policy 4.10 (Reference Tables of HLA Antigen Values and Split Equivalences) Public Comment: July 31, 2017 October
Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005)
Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005) Stephen Spellman Research Manager NMDP Scientific Services Maria Brown Scientific Services Specialist Data Management Conference 2007 1
Diversity and Frequencies of HLA Class I and Class II Genes of an East African Population
Open Journal of Genetics, 2014, 4, 99-124 Published Online April 2014 in SciRes. http://www.scirp.org/journal/ojgen http://dx.doi.org/10.4236/ojgen.2014.42013 Diversity and Frequencies of HLA Class I and
HLA Mismatches. Professor Steven GE Marsh. Anthony Nolan Research Institute EBMT Anthony Nolan Research Institute
HLA Mismatches Professor Steven GE Marsh HLA Mismatches HLA Genes, Structure, Polymorphism HLA Nomenclature HLA Mismatches in HSCT Defining a mismatch HLA Mismatches HLA Genes, Structure, Polymorphism
DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS
DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS The definitions below are intended as general concepts. There will be exceptions to these general definitions. These definitions do not imply any specific
Validation of the MIA FORA NGS FLEX Assay Using Buccal Swabs as the Sample Source
S. Krishnakumar, M. Li, C. Wang, M, Osada, R. Kuehn, M. Fukushima and Y. Thorstenson Immucor, Inc. S. Krishnakumar, M. Li, C. Wang, M, Osada, R. Kuehn, M. Fukushima and Y. Thorstenson Immucor, Inc. Introduction
Supporting Information
Supporting Information Honegger et al. /pnas.0 HCV proteins Core E E P NS NS NSA NSB NSA NSB HCV peptide pools 9 Fig. S. HCV proteins represented in the nine peptide pool arrays used for the IFN-γ ELISpot
Documentation of Changes to EFI Standards: v 5.6.1
Modified Standard B - PERSONNEL QUALIFICATIONS B1.000 The laboratory must employ one or more individuals who meet the qualifications and fulfil the responsibilities of the Director/Co-Director, Technical
The MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK
The MHC and Transplantation Brendan Clark Transplant Immunology, St James s University Hospital, Leeds, UK Blood Groups Immunofluorescent staining has revealed blood group substance in the cell membranes
Significance of the MHC
CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
AG MHC HLA APC Ii EPR TAP ABC CLIP TCR
!! AG MHC HLA APC Ii EPR TAP ABC CLIP TCR Antigen Major Histocompartibility Complex Human Leukocyte Antigen Antigen Presenting Cell Invariant Chain Endoplasmatic Reticulum Transporters Associated with
CPT Codes for Pharmacogenomic Tests
CPT s for Pharmacogenomic Tests The table below lists CPT codes and lab fee information for pharmacogenomic tests as established by the Centers for Medicare and Medicaid Services. It was compiled by the
HLA and new technologies. Vicky Van Sandt
HLA and new technologies. Vicky Van Sandt Life-threatning malignant and non malignant blood disorders can be cured by hematopoetic stem cell transplantation (HSCT). GVHD is the 2nd most prevalent cause
A clear path forward AVAILABLE NOW THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
AVAILABLE NOW A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test that assesses organ
Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT
Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,
FONS Nové sekvenační technologie vklinickédiagnostice?
FONS 2010 Nové sekvenační technologie vklinickédiagnostice? Sekvenování amplikonů Sequence capture Celogenomové sekvenování FONS 2010 Sekvenování amplikonů Amplicon sequencing - amplicon sequencing enables
Historical definition of Antigen. An antigen is a foreign substance that elicits the production of antibodies that specifically binds to the antigen.
Historical definition of Antigen An antigen is a foreign substance that elicits the production of antibodies that specifically binds to the antigen. Historical definition of Antigen An antigen is a foreign
IMMUNOLOGY. Elementary Knowledge of Major Histocompatibility Complex and HLA Typing
IMMUNOLOGY Elementary Knowledge of Major Histocompatibility Complex and HLA Typing Tapasya Srivastava and Subrata Sinha Department of Biochemistry All India Institute of Medical Sciences New Delhi - 110029
National Marrow Donor Program HLA-Matching Guidelines for Unrelated Marrow Transplants
Biology of Blood and Marrow Transplantation 9:610-615 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0910-0003$30.00/0 doi:10.1016/s1083-8791(03)00329-x National Marrow
How to Find an Unrelated Donor Theory & Technology
How to Find an Unrelated Donor Theory & Technology Carlheinz R. Müller Zentrales Knochenmarkspender-Register für die Bundesrepublik Deutschland (ZKRD) Ulm, Germany How to Find an Unrelated Donor HLA-Basics
A clear path forward COMING SOON THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
COMING SOON A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test which assesses organ
Allele and Haplotype Frequencies of Human Leukocyte Antigen-A, -B, -C, -DRB1, and -DQB1 From Sequence- Based DNA Typing Data in Koreans
Original Article Diagnostic Immunology Ann Lab Med 2015;35:429-435 http://dx.doi.org/10.3343/alm.2015.35.4.429 ISSN 2234-3806 eissn 2234-3814 Allele and Haplotype Frequencies of Human Leukocyte Antigen-A,
Immunogenetics in SARS: a casecontrol
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES MHL Ng 吳香玲 SH Cheng 鄭淑恆 KM Lau 劉建盟 GM Leung 梁卓偉 US Khoo 邱瑋璇 BCW Zee 徐仲鍈 JJY Sung 沈祖堯 Key Messages 1. Human leukocyte antigen (HLA) genotypes from 102
Treatment of Chronic Antibody Mediated Rejection
Treatment of Chronic Antibody Mediated Rejection Robert A. Montgomery MD, DPhil Professor of Surgery Director of the NYU Langone Transplant Institute Disclosures: Served on Advisory Boards for Genentech
EBMT2008_1_21:EBMT :06 Pagina 46 * CHAPTER 3. Immunogenetics of allogeneic HSCT * 3.1. The role of HLA in HSCT. J.M.
EBMT2008_1_21:EBMT2008 6-11-2008 9:06 Pagina 46 * CHAPTER 3 Immunogenetics of allogeneic HSCT * 3.1 The role of HLA in HSCT J.M. Tiercy EBMT2008_1_21:EBMT2008 6-11-2008 9:06 Pagina 47 CHAPTER 3.1 HLA and
Supplementary Figure 1 Dosage correlation between imputed and genotyped alleles Imputed dosages (0 to 2) of 2-digit alleles (red) and 4-digit alleles
Supplementary Figure 1 Dosage correlation between imputed and genotyped alleles Imputed dosages (0 to 2) of 2-digit alleles (red) and 4-digit alleles (green) of (A) HLA-A, HLA-B, (C) HLA-C, (D) HLA-DQA1,
10/18/2012. A primer in HLA: The who, what, how and why. What?
A primer in HLA: The who, what, how and why What? 1 First recognized in mice during 1930 s and 1940 s. Mouse (murine) experiments with tumors Independent observations were made in humans with leukoagglutinating
Virtual Crossmatch in Kidney Transplantation
Virtual Crossmatch in Kidney Transplantation Shiva Samavat Associate Professor of Nephrology Labbafinejad Hospital SBMU 2018.11.21 All transplant candidates are screened to determine the degree of humoral
MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH
MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH TEJASWINI M. DHAWALE, M.D. HEME FELLOWS CONFERENCE NOVEMBER 08, 2013 CASE PRESENTATION 51 yo M with history of MDS (unilinear
Significance of the MHC
CHAPTER 8 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com
Transplant Webinar Series: Ep. 6 Donor Selection for Haematopoietic Stem Cell Transplantation Future Webinars The Role of NGS in the Transplant Setting Featuring Dr Sujatha Krishnakumar Sirona Genomics,
Cover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.
CHAPTER 3 LABORATORY PROCEDURES
CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Clinical Transplantation Laboratory (CTL) 3rd Floor Tower Wing Guy's Hospital SE9 1RT Contact: Jeremy Skinner Tel: +44 (0)2071881713 E-Mail:
HLA-DQA1 and DQB1 Genotyping in Individuals with Family History of Gastritis
ADVANCES IN BIORESEARCH, Vol. 2 [1] June 2011: 40-46 Society of Education, India http://www.soeagra.com/abr.htm ISSN 0976-4585 RESEARCH ARTICLE HLA-DQA1 and DQB1 Genotyping in with Family Nibras S. Al-Ammar
Significance of the MHC
CHAPTER 8 Major Histocompatibility Complex (MHC) What is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) - MHC molecules were initially discovered during studies aimed
Human Leukocyte Antigens and donor selection
Human Leukocyte Antigens and donor selection Duangtawan Thammanichanond, MD. PhD. Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University Outline
The Major Histocompatibility Complex (MHC)
Advanced molecular immunology-2011 The Major Histocompatibility Complex (MHC) Youmin Kang 2011.04.06 Activation IFN-g IL-4 IL-2 YYYYYY YYYYY B cells MHC class II pathway Discovery of MHC MHC Class I pathway
New trends in donor selection in Europe: "best match" versus haploidentical. Prof Jakob R Passweg
New trends in donor selection in Europe: "best match" versus haploidentical Prof Jakob R Passweg HSCT change in donor type: 1990-2015 9000 H S C T 8000 7000 6000 5000 4000 HLA identical sibling/twin Haplo-identical
Minutes Tissue Typers Meeting Aarhus, 21st September 2018
Minutes Tissue Typers Meeting Aarhus, 21st September 2018 Location: Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, relocation to C104 patiently accepted by all participants.
Patient and Partner Consult Report
Patient and Partner Consult Report Clinical History History of primary infertility for a period of about 2 years o Including 6 failed IUI cycles and 3 failed IVF cycles Low success rate of embryos surviving
25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?
6/19/212 KPD Webinar Series: Part 3 Demystifying the OPTN Kidney Paired Donation Pilot Program Unacceptable HLA antigens: The key to finding a compatible donor for your patient M. Sue Leffell, Ph.D. J.
Annual Report HISTOCOMPATIBILITY. and IMMUNOGENETICS
HISTOCOMPATIBILITY and IMMUNOGENETICS Annual Report 2013 Contents: 1. Introduction 2. Observations on the Schemes 3. Scheme participation in 2013 4. 2013 Annual Participant Meeting 5. For 2014... 1 1.
Relationship Between HLA-DMA, DMB Alleles and Type 1 Diabetes in Chinese
HK J Paediatr (new series) 2005;10:20-25 Relationship Between HLA-DMA, DMB Alleles and Type 1 Diabetes in Chinese YM SANG, C YAN, C ZHU, GC NI, YM HU Abstract Key words The Human Leucocyte Antigen (HLA)-DMA
Prediction and Prevention of Type 1 Diabetes
Prediction and Prevention of Type 1 Diabetes Helping to defuse the diabetes The number of people in the world currently with type 1 diabetes is around 17 million and increasing rapidly. Already there are
10/7/ Immediate Action, Quest Diagnostics Nichols Institute, Valencia
REDIRECTS Please Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date Page
HOST-PARASITE INTERPLAY
HOST-PARASITE INTERPLAY Adriano Casulli EURLP, ISS (Rome, Italy) HOST-PARASITE INTERPLAY WP3 (parasite virulence vs human immunity) (Parasite) Task 3.1: Genotypic characterization Task 3.6: Transcriptome
Marcelo Fernandez Vina Conflict of Interest: Co-Founder Sirona Genomics
Marcelo Fernandez Vina Conflict of Interest: Co-Founder Sirona Genomics Next Generation Sequencing (NGS) and its Role in Transplantation Marcelo A. Fernández Viña, Ph.D. Professor Department of Pathology
Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale
Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale Pooled Platelets (Buffy Coat Derived) Adult dose from 4 ABO-identical donors
Recent Research Advances in Drug Induced Liver Injury
Recent Research Advances in Drug Induced Liver Injury Timothy M. Wright, MD Global Head of Translational Sciences Novartis Institutes of Biomedical Research, Cambridge, MA University of Michigan, Ann Arbor,
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Thesis Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Dr. Róbert Langer, Ph.D. Consultant:
Transplantation and Cancer
Transplantation and Cancer Immunology Bởi: OpenStaxCollege The immune responses to transplanted organs and to cancer cells are both important medical issues. With the use of tissue typing and anti-rejection
Diabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated
Diabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated pathologically with specific microvascular and macrovascular complications.
AmoyDx TM BRAF V600E Mutation Detection Kit
AmoyDx TM BRAF V600E Mutation Detection Kit Detection of V600E mutation in the BRAF oncogene Instructions For Use Instructions Version: B3.1 Date of Revision: April 2012 Store at -20±2 o C 1/5 Background
Basel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva
Basel - 6 eptember 2012 J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Outline the HLA system is (a) complex anti-hla immunisation and alloreactivity
attomol HLA-B*27-Realtime LT 2 Assay for the detection of the human HLA-B*27-locus using LightCycler (Do not use for tissue typing!
attomol HLA-B*27-Realtime LT 2 Assay for the detection of the human HLA-B*27-locus using LightCycler (Do not use for tissue typing!) For in vitro diagnostic use only! 50 determinations Order number: 95
BDC Keystone Genetics Type 1 Diabetes. Immunology of diabetes book with Teaching Slides
BDC Keystone Genetics Type 1 Diabetes www.barbaradaviscenter.org Immunology of diabetes book with Teaching Slides PRACTICAL Trailnet screens relatives and new onset patients for autoantibodies and HLA
RealLine Mycoplasma genitalium Str-Format
Instructions for use ASSAY KIT FOR THE QUALITATIVE DETECTION OF MYCOPLASMA GENITALIUM DNA BY REAL-TIME PCR METHOD In vitro Diagnostics () VBD4396 96 Tests valid from December 2018 Rev06_1218_EN Page 1
PCR Starter Kit. For MiniAmp and MiniAmp Plus PCR systems USER GUIDE USER GUIDE. Part. No Revison C.0
USER GUIDE USER GUIDE PCR Starter Kit For MiniAmp and MiniAmp Plus PCR systems Part. No. 000704 Revison C.0 For Research Use Only. Not for use in diagnostic procedures. Manufacturer's address: Life Technologies
Profiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009
Profiling HLA motifs by large scale peptide sequencing 2009 Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009 HLA Background The human leukocyte antigen system (HLA) is the
HLA Disease Associations Methods Manual Version (July 25, 2011)
HLA Disease Associations Methods Manual Version 0.1.0 (July 25, 2011) HLA Disease Associations: Detecting Primary and Secondary Disease Predisposing Genes Available online at: The Immunology Database and
Osteoclast Culture Kit
K-ASSAY KAMIYA BIOMEDICAL COMPANY Osteoclast Culture Kit For the culture of Osteoclasts from precursor cells. Cat. No.: CC-107 Rat Osteoclast Precursor Cells, V-1 CC-109 Mouse Osteoclast Precursor Cells,
Effects of age-at-diagnosis and duration of diabetes on GADA and IA-2A positivity
Effects of age-at-diagnosis and duration of diabetes on GADA and IA-2A positivity Duration of diabetes was inversely correlated with age-at-diagnosis (ρ=-0.13). However, as backward stepwise regression
Genetic Testing for Pharmacogenetics
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below (1.0 and 3.0) Additional Information: None Prevea360 Health Plan
Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection
Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Alison Logan Transplantation Laboratory Manchester Royal Infirmary Haematopoietic progenitor cell transplants
The Relationship between Minor Histocompatibility Antigens and Graft Versus Host Disease in Unrelated Peripheral Blood Stem Cell Transplants
mhags and GVHD Page 1 The Relationship between Minor Histocompatibility Antigens and Graft Versus Host Disease in Unrelated Peripheral Blood Stem Cell Transplants Running Title: mhags and GVHD Conflict
Implementation Inoculate positive Alicyclobacillus sample from BAT-Agar into incubation tube (Fig 1) with induction broth.
Guaiacol detection kit (Art.No. 2.04737.991) page 1/5 1. Application Enzyme assay for the detection of Guaiacol-producing Alicyclobacillus ssp. in the beverage and fruit compound industry. The Guaiacol
Genotyping of HLA-class-I and II by PCR-SSP of Patients with. Recurrent Aphthous Stomatitis
Original Article Genotyping of HLA-class-I and II by PCR-SSP of Patients with * Mustafa M. Saliah** Ahmed A.Al-Hassan*** Ammra J. Al-Nema**** Ahmed Kadem***** BSc, PhD BDS Vet, PhD MD, MSc MSc Fac Med
STANDARD CONNECTORS. ENFIT CONNECTORS. EITHER WAY, WE KEEP YOU CONNECTED.
MIC-KEY* & MIC* G, J, & GJ, FEEDING TUBE KITS Extension Sets ENFIT CONNECTORS Continuous Feed Bolus Feed Medication STANDARD CONNECTORS. ENFIT CONNECTORS. EITHER WAY, WE KEEP YOU CONNECTED. No matter what
OU Human Physiology: Transplantation and Cancer Immunology *
OpenStax-CNX module: m56626 1 OU Human Physiology: Transplantation and Cancer Immunology * Heather Ketchum Eric Bright Based on Transplantation and Cancer Immunology by OpenStax This work is produced by
ASSESSMENT OF THE RISK FOR TYPE 1 DIABETES MELLITUS CONFERRED BY HLA CLASS II GENES. Irina Durbală
ASSESSMENT OF THE RISK FOR TYPE 1 DIABETES MELLITUS CONFERRED BY HLA CLASS II GENES Summary Irina Durbală CELL AND MOLECULAR BIOLOGY DEPARTMENT FACULTY OF MEDICINE, OVIDIUS UNIVERSITY CONSTANŢA Class II
Clinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
HLA AND KIR GENE POLYMORPHISM IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
FROM THE DEPARTMENT OF LABORATORY MEDICINE, DIVISION OF CLINICAL IMMUNOLOGY KAROLINSKA INSTITUTET, STOCKHOLM, SWEDEN HLA AND KIR GENE POLYMORPHISM IN HEMATOPOIETIC STEM CELL TRANSPLANTATION Marie Schaffer
Use of PCR with Sequence-specific Primers for High-Resolution Human Leukocyte Antigen Typing of Patients with Narcolepsy
Original Article Woo HI, et al. Diagnostic Immunology Ann Lab Med 2012;32:57-65 ISSN 2234-3806 eissn 2234-3814 Use of PCR with Sequence-specific Primers for High-Resolution Human Leukocyte Antigen Typing
T-cell receptor feature. Antibody/antigen interaction. Major Histocompatibility Complex. Antigen processing. Antigen presentation
ntibody/antigen interaction Major Histocompatibility Complex ntigen processing ntigen presentation PC/T-cell interaction T-cell receptor feature CD4+ T-Cell HL/peptide/TCR complex CD8+ T-Cell Proteasome
Samples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
Osteoclast Culture Kit
K-ASSAY Osteoclast Culture Kit For the culture of Osteoclasts from precursor cells. Cat. No.: CC-107 Rat Osteoclast Precursor Cells, V-1 For Research Use Only. 1 Rev. 091708 K-ASSAY PRODUCT INFORMATION
Samples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
Protocol. Preparation Protocol for the Target-Ready Vevo MicroMarker Contrast Agent
Protocol Preparation Protocol for the Target-Ready Vevo MicroMarker Contrast Agent System Compatibility: This guide contains instructions and suggestions for work on the Vevo2100, VevoLAZR, Vevo 3100 systems
Building and validating a prediction model for paediatric type 1 diabetes risk using next generation targeted sequencing of class II HLA genes
Received: 28 September 2016 Revised: 26 June 2017 Accepted: 10 July 2017 DOI: 10.1002/dmrr.2921 RESEARCH ARTICLE Building and validating a prediction model for paediatric type 1 diabetes risk using next
α chain β chain C N C N β 2 α 1 β 1 α 2
a α chain c β chain C N C N β 2 m α chain b d N C N C β 1 α 2 Supplemental Figure 1 Major histocompatibility complex (MHC) class I and class II structures. (a, b)representation of the structure of the
HLA Association in SLE patients from Lahore-Pakistan
HLA Association in SLE patients from Lahore-Pakistan Nageen Hussain 1 *, Ghazala Jaffery 2, Anjum Nasim Sabri 1, Shahida Hasnain 1 1 Quaid-e-Azam University of the Punjab, Department of Microbiology and
HLA-C, DRB1 and DQB1 alleles involved in genetic predisposition to psoriasis vulgaris in the Slovak population
Folia Microbiol (2013) 58:319 324 DOI 10.1007/s12223-012-0213-7 HLA-C, DRB1 and DQB1 alleles involved in genetic predisposition to psoriasis vulgaris in the Slovak population Ivana Shawkatová & Juraj Javor
altona RealStar Instructions for Use RealStar CMV PCR Kit /2017 EN DIAGNOSTICS
altona DIAGNOSTICS Instructions for Use RealStar CMV PCR Kit 1.2 08/2017 EN RealStar RealStar CMV PCR Kit 1.2 For research use only! (RUO) 021202 INS-021200-EN-S01 48 08 2017 altona Diagnostics GmbH Mörkenstr.
Run glycans up to 5x faster than HILIC
FAST GLYCAN LABELING AND ANALYSIS TECHNOLOGY Run glycans up to 5x faster than HILIC HI-RES ANALYSIS AND ID IN MINUTES Run Your Glycans in Record Time High-Resolution Glycan Identification and Quantitation
HLA Class II Allele and Haplotype Frequencies in Iranian Patients with Acute Myelogenous Leukemia and Control Group
ORIGINAL ARTICLE Iran J Allergy Asthma Immunol September 2006; 5(3):115-119 HLA Class II Allele and Haplotype Frequencies in Iranian Patients with Acute Myelogenous Leukemia and Group Abdolfattah Sarafnejad
Alleles: the alternative forms of a gene found in different individuals. Allotypes or allomorphs: the different protein forms encoded by alleles
Nomenclature Alleles: the alternative forms of a gene found in different individuals Allotypes or allomorphs: the different protein forms encoded by alleles Genotype: the collection of genes in an individual,
Patient Consult Report
Patient Consult Report Clinical History Currently 36 years old History of firstborn son now about 5 years old followed by secondary recurrent pregnancy loss with 9 losses (all between 6 and 11 weeks) over
HLA Class I and II Genotyping by PCR-SSO in Patients with Type-1 Diabetes Mellitus
HLA THE CLASS IRAQI POSTGRADUATE I AND II GENOTYPING MEDICAL JOURNAL HLA Class I and II Genotyping by PCR-SSO in Patients with Type-1 Diabetes Mellitus Ahmed A. Al-Hassan*, Anwar Mohammad*, Batool H. Al-Ghurabi**,
HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis
Gut 999;4:9 40 9 Laboratory for Experimental Internal Medicine, Academic Medical Centre, G2 0, Meibergdreef 9, 0 AZ Amsterdam, The Netherlands P C F Stokkers P H Reitsma GNJTytgat SJHvanDeventer Correspondence
Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset
Diabetologia (2009) 52:2513 2521 DOI 10.1007/s00125-009-1539-9 ARTICLE Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset Y. Kawabata